Intracranial haemorrhage is a serious lifethreatening complication that occurs during warfarin oral anticoagulant therapy with mortality in excess of 50% 1, 2 . While the incidence of spontaneous intracerebral haemorrhage is estimated to be between 10 to 20 per 100,000 population per year, it is seven to 10 times higher in patients receiving oral anticoagulant therapy [2] [3] [4] . Large haematoma volume and early haematoma increase in size are known predictors of poor outcome in spontaneous intracerebral haemorrhage, and patients presenting with oral anticoagulant therapy-related intracerebral haemorrhage have increased risks of haematoma expansion and mortality compared with spontaneous intracerebral haemorrhage 5 .
Oral anticoagulant therapy may cause the development of intracerebral haemorrhage by blocking vitamin K-dependent clotting homeostasis or by unmasking pre-existing subclinical intracerebral bleeding 6 . However, poor outcome in oral anticoagulant therapy-related intracerebral haemorrhage has generally been attributed to continual haematoma growth before correction of prothrombin time/international normalised ratio (PT/ INR). Patients presenting with oral anticoagulant SuMMARy We report our initial experience using Profilnine SD, a 3-Factor prothrombin complex concentrate (PCC) in combination with fresh frozen plasma and vitamin K in seven patients admitted to our neurointensive care unit with oral anticoagulation therapy-related intracranial haemorrhage over a six-month period, to achieve rapid normalisation of the international normalised ratio (INR) and allow surgical evacuation when indicated.
Four patients presented with subdural haematomas while three had intracerebral haematomas. Six of seven patients had admission INR in the appropriate therapeutic range for oral anticoagulation therapy. The median dose of PCC administered was 28.5 IU/kg body weight (interquartile range 21.3 to 38.5 IU/kg). All four patients with subdural haematoma underwent surgical evacuation once INR was less than 1.5. Median time from computed tomography diagnosis to surgery was 275 minutes (range 102 to 420 minutes). The median time to INR normalisation post-PCC administration was shorter, at 85 minutes (range 50 to 420 minutes) for the four patients who survived, versus 10 hours (range 9 to 44 hours) in the three patients who died. Two of the three patients who died had haematoma increase, worsening midline shift and subfalcine herniation, leading to withdrawal of therapy.
Prothrombin complex concentrates should be considered for use in the urgent reversal of INR in oral anticoagulation therapy-related intracranial haemorrhage, potentially halting haematoma expansion and expediting urgent neurosurgical intervention, although data from randomised controlled trials is still lacking. The literature supporting the use of PCC is reviewed and a protocolised emergent treatment algorithm is proposed, which may help achieve earlier consistent normalisation of the INR. therapy-related intracerebral haemorrhage thus mandate rapid PT/INR normalisation to decrease the risk of early haematoma enlargement and to facilitate early neurosurgical evacuation when indicated.
Recent national, including British and Australasian, guidelines 7 for rapid reversal of warfarin coagulopathy in life-threatening emergencies have recommended the use of prothrombin complex concentrates (PCC) in combination with fresh frozen plasma (FFP) and vitamin K for life-threatening emergencies. Prothrombin complex concentrates, which contain factors II, IX, X and variable quantities of VII, have been shown to reliably normalise INR in combination with FFP (for factor VII) within 10 to 60 minutes of administration. The use of PCC in combination with lower volumes of FFP and vitamin K will further reduce the risk of fluid overload and congestive heart failure in patients with underlying cardiovascular disease.
We report our initial experience using PCC in combination with FFP in patients admitted to our neurointensive care unit with oral anticoagulant therapy-related intracerebral haemorrhage. Apart from the fear of causing thrombotic complications, two other major impediments that have limited the use of PCC in this setting are the limited availability of PCC in some centres and the lack of knowledge on its use among treating physicians. PCC has been available in our institution since September 2007 and this pilot regimen was established in consultation with our haematology service, after recognising that our existing therapeutic regimen using FFP and vitamin K alone was not reliable in consistently achieving early normalisation of INR to support surgical treatment when indicated.
METHODS
We reviewed all consecutive patients with oral anticoagulant therapy-related intracranial haemorrhage admitted to our 18-bed acute tertiarylevel neurointensive care unit and treated with PCC from January to June 2008, after approval from our institutional domain-specific research board. All patients were on warfarin oral anticoagulant therapy for clinically appropriate indications, had an INR of greater than 1.5 at presentation, computed tomography (CT) diagnosis of intracranial haemorrhage and were admitted directly through the emergency department. The patients were reviewed for use of PCC in consultation with the haematologist after acute resuscitation and stabilisation. Warfarin anticoagulation was reversed with Profilnine SD (Grisols Biologicale Inc, Los Angeles, CA, uSA), a 3-Factor PCC containing per 100 u of factor IX, 148 u of factor II and 64 u of factor X, FFP (as an adjunct source of Factor VII) and vitamin K. One patient also received activated recombinant factor VII (rFVIIa) or NovoSeven (Novo Nordisk, Denmark) prior to PCC treatment.
The data collected included patient demographics, comorbidities and clinical parameters, indications, duration and intensity of warfarin oral anticoagulant therapy, initial post-treatment coagulation profile, presenting CT brain findings, initial and repeat dosages and timing of blood products administrated. Outcome at 30 days was assessed using the Glasgow Outcome Score. Major side-effects of oral anticoagulant therapy reversal, including thromboembolic complications (superficial thrombophlebitis, deep vein thrombosis, pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation) and coronary thrombosis were documented.
RESuLTS
A total of seven patients received PCC for oral anticoagulant therapy-related intracranial haemorrhage during the six-month study period. Table 1 shows the patient demographics, clinical characteristics and neuroradiological findings. The majority of the patients were elderly and on oral anticoagulant therapy for prevention of embolic strokes due to underlying atrial fibrillation. Median duration of oral anticoagulant therapy was four years (range two to 20 years) with one patient on warfarin for the past 20 years after mitral valvotomy for mitral stenosis with atrial fibrillation. The patients frequently had other systemic comorbidities. Four out of the seven (57%) patients had subdural haematomas with significant deterioration in consciousness level (Glasgow Coma Scale 3 to 9) and they all required urgent surgical evacuation. The presence of midline shift and intraventricular haemorrhage extension are known predictors of poor outcome. Almost all our patients (6/7 patients or 85.7%) had midline shift on the presenting CT scan, although only one patient with intracerebral haemorrhage had intraventricular haemorrhage extension. The mean maximum diameter of the subdural haematomas in our four patients was 18.1 mm (range 11.5 to 33 mm) while the mean maximum diameter of the intracerebral haemorrhage in our three patients was 45.3 mm (range 15 to 61 mm).
Most patients had admission INR within or close to the therapeutic range of 2 to 3, except for one patient whose INR was 7.74. The reason for this patient's over-anticoagulation is uncertain, as her previous INR profiles had been within therapeutic range during outpatient oral anticoagulant therapy monitoring. Table 2 shows the types and quantity of blood products administered to the patients for oral anticoagulant reversal. The dose of PCC administered ranged from 1000 to 3000 Iu (equivalent to a median of 28.5 Iu/kg body weight). One patient received rFVIIa initially, which resulted in rapid correction of coagulopathy but was associated with a rebound of INR to greater than 1.5 post-surgery 18 hours later, necessitating administration of PCC and more FFP. There was wide variation in the time when PT/INR was checked post-administration of PCC as there had been no protocol in place to routinely check INR early post-correction in this initial series of patients. Three patients had PT/INR checked early post- 
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Data are presented as median (IQR, interquartile range) where appropriate. GCS=Glasgow Coma Scale, GOS=Glasgow Outcome Score. † One patient's follow-up CT scan showed interval worsening of acute subdural haematomas to from 11.5 mm previously to 22 mm, with development of hydrocephalus and subflacine and uncal herniation. Another patient's computed tomography scan showed interval enlargement of the frontoparietal haematoma in its inferior aspect, significant mass-effect and diffuse cerebral oedema and development of subfalcine and tonsillar hernation. Both patients eventually died. correction and demonstrated INR less than or equal to 1.3 within 50, 80 and 90 minutes respectively. All four patients with subdural haematomas underwent surgical evacuation once INR was less than 1.5 with median time from CT diagnosis to surgery of 275 minutes (range 102 to 420 minutes). Four of seven patients had good neurological outcome (Glasgow Outcome Score 4) at 30 days and subsequently underwent neuro-rehabilitation ( Table 3 ). The median time to INR normalisation post-PCC administration was shorter at 85 minutes (range 50 to 420 minutes) for the four patients who survived, in contrast to the three patients who died (median time 10 hours, range 9 to 44 hours). Two of the three patients who died had CT evidence of haematoma increase, worsening midline shift and subfalcine herniation that resulted in a decision for withdrawal of therapy. One patient, despite having received a relatively lower dose of 1000 Iu (14.9 Iu/kg) PCC, developed pulmonary embolism from deep venous thrombosis. This was diagnosed on day three post-PCC treatment.
DISCuSSION
The incidence of fatal oral anticoagulant therapyrelated intracerebral bleeding has been reported to be approximately 1% per annum in clinical trials of warfarin used for stroke prevention in nonvalvular atrial fibrillation 8 . Enlargement of haematoma is associated with neurological deterioration and poorer outcome, and it is now recognised that early haematoma growth occurs to a clinically significant degree in 38% of cases of intracerebral haemorrhage 9 . Warfarin use, reflected in an elevated PT or INR, is a risk factor for intracranial haematoma expansion with odds ratio of 6.2, reported in a study by Flibotte JJ et al 5 . The degree of INR elevation has been shown to be directly correlated with mortality at three months by Franke CL et al 3 . Rapid reversal of warfarin coagulopathy is therefore essential to facilitate emergency neurosurgical intervention and to prevent haematoma growth.
The current dominant management strategy of warfarin cessation, FFP transfusion and vitamin K administration may not be an effective way of reversing warfarin coagulopathy in a medical emergency such as oral anticoagulant therapy-related intracranial haemorrhage. Vitamin K administration entails a small risk of anaphylaxis, may induce modest haemodynamic changes in patients with cardiac dysfunction 10 , which is a common co-existing medical problem in patients on warfarin, and should not be used as monotherapy because it generally takes more than 12 to 24 hours to completely normalise the INR. The use of FFP, at the recommended dose of 15 to 20 ml/kg, implies the infusion of large volumes of plasma, which not only takes several hours to complete, but can also lead to volume overload and heart failure, especially in those with cardiac impairment. In addition, the concentration of clotting factors in each batch of FFP varies substantially, making the efficacy of FFP transfusion unpredictable. FFP also requires blood group typing and thawing before transfusion. The circulating levels of factor IX may remain low (resulting in incomplete haemostasis) despite replacement of all other clotting factors with FFP. Finally, FFP transfusion is associated with several potential adverse reactions, including transfusion-related acute lung injury, allergic reactions and blood-borne infections.
With the current FFP and vitamin K regimens, time from initiation of therapy to normalisation of INR varies widely and may even exceed 24 hours, depending on the processes in place for the rapid initiation of therapy and the time needed to transit the chain of emergency care before definitive stroke therapy is instituted 11 .
In several earlier comparison studies involving patients with intracranial haemorrhage, PCC more completely and promptly reversed laboratory markers of oral anticoagulant therapy [12] [13] [14] [15] . However, in a small prospective randomised trial by Boulis et al, superior laboratory reversal in the PCC arm did not improve neurologic outcomes, even though there was a higher complication rate (related to fluid overload) in the FFP group 15 . Huttner at al demonstrated that both the incidence and extent of haematoma enlargement depended on the degree of elevation of the INR, and that a completely reversed INR rather than the prescribed treatment per se seemed to prevent haematoma enlargement 16 .
While correction with PCC is not known to be any more beneficial when compared with patients who had INR normalised early with FFP and vitamin K, it more reliably achieves early INR normalisation, and thus may have a pivotal role in any acute treatment regimen to improve outcome. Based on recent British and Australasian guidelines on the use of PCC in major or significant haemorrhage, our neurointensive care unit has recently moved to treat oral anticoagulant therapy-related intracerebral haemorrhage with greater urgency using PCC, in consultation with our haematologist. As a guide to dosing, the British Committee for Standards in Haematology recommends 5 mg of vitamin K and 50 Iu/kg of PCC or 15 ml/kg of FFP 17 . The Australasian Society of Thrombosis and Haemostasis recommends 5 to 10 mg of vitamin K, 25 to 50 Iu/kg of PCC and 150 to 300 ml of FFP 18 .
It is also important to note that not all PCC products are identical. 4-Factor PCCs contain factors II, VII, IX and X, while 3-Factor PCCs contain only limited amounts of factor VII and require the adjunctive use of FFP. The usual recommended dose of PCC is 25 to 50 Iu/kg and some investigators have suggested that individualised PCC dosing may be more rapid and cost-effective, and reduce the main side-effects of PCC, namely thromboembolism and DIVC 19, 20 . In our institution, we estimate that using PCC at these recommended doses is not more expensive than using processed donor FFP to achieve the same desired end-point. This is not the case with the use of rFVIIa, which is very much more costly by comparison and has a much shorter half-life, with the potential for INR rebound, as shown in the single case in our series. While rFVIIa has not been shown to improve mortality due to higher arterial thrombotic risks, despite reducing haematoma growth in a recent randomised controlled trial of spontaneous intracerebral haemorrhage 21 , no study has been performed to evaluate the use of PCC in a similar setting.
Delayed reversal of oral anticoagulant therapy is a persistent problem even in a life-threatening emergencies such as intracranial haemorrhage. This is unsatisfactory in an era of acute stroke intervention 22 . Although intracerebral haemorrhage typically account for 70% of all oral anticoagulant therapy-related intracranial haemorrhages, with the remainder made up of subdural haematomas 1 , our case series had a predominance of subdural haematomas (57%) as the presenting pathology, which required urgent surgical evacuation. This report thus highlights a useful application of early INR reversal with PCC treatment regimens in facilitating surgical management. The main limitations of our case series are the wide variance in completion times of the PCC and FFP transfusion, the variance in the dosing per unit body weight of PCC and the timing of laboratory confirmation of INR normalisation. INR normalisation is an important trigger for surgical intervention and the earliest possible intervention based on an understanding of the pharmacokinetics of PCC use may lead to improved outcomes. Despite these limitations, the study has allowed us to review the key steps needed to formulate an early INR reversal algorithm which includes the use of PCC for this group of patients. (Figure 1 ).
CONCLuSIONS
Although oral anticoagulant therapy-related intracranial haemorrhage is a serious and life-threatening complication, standardised treatment guidelines to rapidly correct the coagulopathy have not been universally adopted. This could reflect the lack of good evidence from randomised controlled trials, with current treatment strategies based on low levels of evidence and a simple pharmacologic approach of rapid and specific replacement of depleted vitamin K-dependent clotting factors in warfarin-induced coagulopathy. until the results from such trials become available, cumulative reports and systematic reviews 7, 23 have demonstrated that the use of PCC can accelerate the correction of coagulopathy in oral anticoagulant therapy-related intracranial haemorrhage, potentially halting haematoma expansion and expediting urgent neurosurgical intervention. While the ideal dosing regimen and risks of this therapy awaits validation in large scale studies, current recommendations will continue to be based on case series and anecdotal experience.
